Neurim Can't Block Teva From Selling Generic Insomnia Drug

By Joel Poultney (May 6, 2022, 3:21 PM BST) -- A judge has refused to let Neurim block Teva from selling a generic version of a melatonin medicine used to treat insomnia while Neurim's infringement suit goes forward, ruling damages would be enough compensation if the company wins.

High Court Judge James Mellor rejected the request from Neurim Pharmaceuticals (1991) Ltd. and its U.K. distributor Flynn Pharma Ltd. in a newly public April 26 judgment, declining to stop Teva UK Ltd. from selling a generic version of the drug before the melatonin patent expires on Aug. 12.

The judge said the companies delayed bringing the application despite having had ample time...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!